Sign up to access all valuation multiples
PharmaNutra SpA is a pharmaceutical company. The company is engaged in the research, design, development, and marketing of nutraceutical supplements and medical devices. The products of the company include SiderAL Folic, UltraMag, Cetilar, and others. The company operates in Europe, the Middle East, South America, the Far East, Asia and others.
2003
118
LTM Revenue $148M
LTM EBITDA $39.8M
$528M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
PharmaNutra has a last 12-month revenue (LTM) of $148M and a last 12-month EBITDA of $39.8M.
In the most recent fiscal year, PharmaNutra achieved revenue of $136M and an EBITDA of $37.3M.
PharmaNutra expects next 12-month revenue of XXX and NTM EBITDA of XXX
See PharmaNutra valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $148M | XXX | $136M | XXX | XXX | XXX |
| Gross Profit | n/a | XXX | $96.1M | XXX | XXX | XXX |
| Gross Margin | n/a | XXX | 71% | XXX | XXX | XXX |
| EBITDA | $39.8M | XXX | $37.3M | XXX | XXX | XXX |
| EBITDA Margin | 27% | XXX | 28% | XXX | XXX | XXX |
| EBIT | $34.2M | XXX | $32.3M | XXX | XXX | XXX |
| EBIT Margin | 23% | XXX | 24% | XXX | XXX | XXX |
| Net Profit | $22.9M | XXX | $19.3M | XXX | XXX | XXX |
| Net Margin | 15% | XXX | 14% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $8.1M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of September 3, 2025, PharmaNutra's stock price is EUR 48 (or $56).
PharmaNutra has current market cap of EUR 461M (or $536M), and EV of EUR 455M (or $528M).
See PharmaNutra trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $528M | $536M | XXX | XXX | XXX | XXX | $2.38 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of September 3, 2025, PharmaNutra has market cap of $536M and EV of $528M.
PharmaNutra's trades at 3.9x EV/Revenue multiple, and 14.1x EV/EBITDA.
Equity research analysts estimate PharmaNutra's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
PharmaNutra has a P/E ratio of 23.4x.
See valuation multiples for PharmaNutra and 15K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $536M | XXX | $536M | XXX | XXX | XXX |
| EV (current) | $528M | XXX | $528M | XXX | XXX | XXX |
| EV/Revenue | 3.6x | XXX | 3.9x | XXX | XXX | XXX |
| EV/EBITDA | 13.3x | XXX | 14.1x | XXX | XXX | XXX |
| EV/EBIT | 15.4x | XXX | 16.3x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | 23.4x | XXX | 27.8x | XXX | XXX | XXX |
| EV/FCF | 22.9x | XXX | 28.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialPharmaNutra's last 12 month revenue growth is 14%
PharmaNutra's revenue per employee in the last FY averaged $1.1M, while opex per employee averaged $0.5M for the same period.
PharmaNutra's rule of 40 is 40% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
PharmaNutra's rule of X is 62% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for PharmaNutra and other 15K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 14% | XXX | 14% | XXX | XXX | XXX |
| EBITDA Margin | 27% | XXX | 28% | XXX | XXX | XXX |
| EBITDA Growth | 18% | XXX | 16% | XXX | XXX | XXX |
| Rule of 40 | 40% | XXX | 42% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 62% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $1.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.5M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 26% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 1% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 47% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| SynBiotic | XXX | XXX | XXX | XXX | XXX | XXX |
| Mega Lifesciences | XXX | XXX | XXX | XXX | XXX | XXX |
| Procter & Gamble Health | XXX | XXX | XXX | XXX | XXX | XXX |
| Abbott India | XXX | XXX | XXX | XXX | XXX | XXX |
| Sanofi India | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
PharmaNutra acquired XXX companies to date.
Last acquisition by PharmaNutra was XXXXXXXX, XXXXX XXXXX XXXXXX . PharmaNutra acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 65K+ M&A deals.
Start Free Trial| When was PharmaNutra founded? | PharmaNutra was founded in 2003. |
| Where is PharmaNutra headquartered? | PharmaNutra is headquartered in Italy. |
| How many employees does PharmaNutra have? | As of today, PharmaNutra has 118 employees. |
| Is PharmaNutra publicy listed? | Yes, PharmaNutra is a public company listed on MIL. |
| What is the stock symbol of PharmaNutra? | PharmaNutra trades under PHN ticker. |
| When did PharmaNutra go public? | PharmaNutra went public in 2017. |
| Who are competitors of PharmaNutra? | Similar companies to PharmaNutra include e.g. SynBiotic, Mega Lifesciences, Procter & Gamble Health, Abbott India. |
| What is the current market cap of PharmaNutra? | PharmaNutra's current market cap is $536M |
| What is the current revenue of PharmaNutra? | PharmaNutra's last 12 months revenue is $148M. |
| What is the current revenue growth of PharmaNutra? | PharmaNutra revenue growth (NTM/LTM) is 14%. |
| What is the current EV/Revenue multiple of PharmaNutra? | Current revenue multiple of PharmaNutra is 3.6x. |
| Is PharmaNutra profitable? | Yes, PharmaNutra is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of PharmaNutra? | PharmaNutra's last 12 months EBITDA is $39.8M. |
| What is PharmaNutra's EBITDA margin? | PharmaNutra's last 12 months EBITDA margin is 27%. |
| What is the current EV/EBITDA multiple of PharmaNutra? | Current EBITDA multiple of PharmaNutra is 13.3x. |
| What is the current FCF of PharmaNutra? | PharmaNutra's last 12 months FCF is $23.0M. |
| What is PharmaNutra's FCF margin? | PharmaNutra's last 12 months FCF margin is 16%. |
| What is the current EV/FCF multiple of PharmaNutra? | Current FCF multiple of PharmaNutra is 22.9x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
